Function

1. Increases human Growth Hormone (hGH)
Increases in endogenous human Growth Hormone (hGH) secretion by the anterior pituitary in conjunction with Growth Hormone Releasing Hormone (GHRH); that is, both Alpha-GPC and GHRH act concertedly to stimulate the release of hGH, naturally;
2. More strength from work-outs and training programs
Acts as a precursor of acetylcholine (ACh); thus, Alpha-GPC activates cholinergic transmission which permits the development of more strength from work-outs and training programs, plus reducing levels of somatostatin in the hypothalamic-pituitary axis;
3. Improved lipotrophic functions in the liver
Elevations in blood and tissue levels of the essential nutrient, choline, which supports improved lipotrophic functions (methyl group transferases) in the liver. Research has shown that fatty liver, a condition associated with obesity, diabetes and heavy alcohol consumption, often leads to cirrhosis of the liver or liver failure. Studies conducted by Alan L. Buchman, M.D., associate professor of medicine at The Feinberg School of Medicine at Northwestern University, have shown that fatty liver can be prevented and possibly even eliminated with increased levels of choline. Alpha-GPC also acts synergistically with the body's store (and/or supplementation) of S-adenosyl-L-methionine (SAM or SAMe) and folic acid, vitamin B12 and vitamin B6 to facilitate methyl group transfers in the brain and liver;
4. Improved balanced and coordination
Produces improved balanced and coordination when combined with 'skill set' practice and training as a result of normalized nerve transmission in the brain, and in cardiac, skeletal and smooth muscles.

Application

Alpha GPC  rapidly delivers choline to the brain across the blood–brain barrier and is a biosynthetic precursor of the acetylcholine neurotransmitter.Alpha GPC is derived from highly purified soy lecithin by companies like Lipoid, VAV Life Sciences, Chemi SPA etc.

Studies have investigated its efficacy for cognitive disorders including stroke and Alzheimer’s Disease. An Italian multicentre clinical trial on 2,044 patients suffering from recent stroke were supplied alpha-GPC in doses of 1,000 mg/day for 28 days and 400 mg three times per day for the five ensuing months. The trial confirmed the therapeutic role of alpha-GPC on the cognitive recovery of patients based on four measurement scales, three of which reached statistical significance.